INTRODUCTION

Phase 2 detoxification enzymes such as NAD(P)H:(quinone-acceptor) oxidoreductase
[quinone reductase (QR)], glutathione S-transferases (GSTs), epoxide hydrolase, and UDPglucuronosyltransferases are induced in cells by electrophilic compounds and phenolic antioxidants (reviewed in refs. 1 and 2). These widely distributed enzymes detoxify electrophiles, thereby protecting cells against the toxic and neoplastic effects of carcinogens. We have previously shown that increases in QR enzyme activity can be induced by low concentrations of antiestrogens in breast cancer cells (3) . Induction of QR enzymatic activity showed unusual reversed pharmacology, being markedly up-regulated by antiestrogen and suppressed by estrogen in breast cancer cells. The antiestrogen regulation of quinone reductase enzymatic activity represents a potentially important pharmacological mechanism for this group of anticancer drugs that had not been previously recognized.
The electrophile response element (EpRE) motif has been identified in the regulatory region of the genes encoding QR and the GST-Ya subunit (4, 5) . This element has been shown to mediate basal expression and its activation by phenolic antioxidants (6) (7) (8) (9) (10) (11) , and it appears to be essential for antiestrogen stimulation (3) . QR expression is upregulated at the transcriptional level through the EpRE by antiestrogen-liganded Estrogen Receptor (ER). Interestingly ERβ is a more potent activator of QR gene transcriptional activity than ERα. Gel shift assays suggest that antiestrogen-mediated induction of QR gene transcriptional activity in MCF7 cells involves a direct transcriptional effect where ERα or ERβ are components of the protein complex that binds the EpRE. However several aspects of antiestrogen regulation of QR transcriptional activity cannot be attributed solely to ER binding to the EpRE and remain to be investigated. This is especially true in light of our previous observations that (1) the time course of induction of QR enzyme activity is relatively slow (with increases in QR mRNA first detectable at 12-16 h after antiestrogen treatment of MCF7 cells, ref. 3) , (2) antiestrogen activation of GST Ya gene transcriptional activity is mediated through an EpRE which is not homologous to the ERE (ref. and -446 of the QR gene promoter introduced upstream of the thymidine kinase gene promoter in the pBLCAT2 vector), pNQO1hARE(mut)-tk-CAT (containing a mutated TRE element), and pNQO1hARE(mut2)-tk-CAT (containing a mutated TRE-like element) have been described previously (9, 10, 12) .
The partial hPMC2 clone, pAD-GAL4-2.1-hPMC2(139-422), obtained from yeast two hybrid screening contains amino acids 139-422 of human XPMC2 cloned in frame with the activation domain of GAL4 in the pAD-GAL4-2.1 phagemid vector (Stratagene, La Jolla, CA).
The partial cDNA clone was released by BamHI/SalI digestion and inserted in frame with the FLAG epitope into BamHI/SalI digested pCMV-Tag2B vector (Stratagene) to make pCMVTag2B-hPMC2(139-422). cDNA encoding amino acids 1-204 was obtained using Access RT-PCR kit from Promega (Madison, WI). Briefly, DNA-free RNA was obtained by treatment of total RNA with DNAaseI in the presence of placental RNase inhibitor for 30 min at 37 C.
After phenol/chloroform extraction and ethanol precipitation, RT-PCR reactions were performed for each RNA sample using 0.25 µg DNA-free total RNA in 1x reaction buffer, 0.2 mM each of dATP, dCTP, dGTP and dTTP, 1 mM MgSO4, 5 u of AMV Reverse Transcriptase, 5 u of Tfl DNA polymerase, and 1 uM each of upstream primer (CGGCCCAGGCGCTGGACGGCAG) and downstream primer (CTATGGCAGCTTCGATATCCGGTG). The first strand cDNA synthesis reactions were performed at 48 C for 45 min, 94 C for 2 min. The second strand cDNA synthesis and PCR amplification reactions were performed at 40 cycles of 94 C for 30 sec, 60 C Novel Regulator of QR Transcriptional Activity for 1 min, 68 C for 2 min, followed by a final extension step at 68 C for 7 min. Amplified cDNA was run on a 1.2% agarose gel and purified using the QIAEX kit from Qiagen (Chatsworth, CA). The cDNA was then cloned into the pCR-Blunt II-TOPO vector to make pCRII-TOPO-hPMC2(1-204) using the Zero Blunt TOPO PCR Cloning Kit from Invitrogen (Carlsbad, CA) and sequenced using the Sequenase Kit (United States Biochemicals, Cleveland, Ohio).
To construct a mammalian expression vector for full-length hPMC2 cDNA, pCRII-TOPO-hPMC2(1-204) was digested with BamHI and EcoRV to release the fragment encoding amino acids 1-204. The fragment was then inserted in frame with the FLAG epitope at the 5'-end and in frame with amino acids 205-422 at the 3' end into BamHI/EcoRV digested pCMVTag2B-hPMC2(139-422) to make pCMV-Tag2B-hPMC2. pGEX2T-hPMC2, which encodes full-length and FLAG-epitope tagged hPMC2 in frame with glutathione-S-transferase (GST) was constructed by NotI/XhoI digestion of pCMV-Tag2B-hPMC2. The insert, which contains cDNA encoding full-length FLAG-hPMC2, was blunted with Klenow and inserted into BamHI digested and blunted pGEX2T (Pharmacia, Piscataway, NJ). pEGFP-hPMC2, which encodes full length hPMC2 in frame with the coding sequence for Green Fluorescent Protein (GFP), was constructed by BamHI/XhoI digestion of pCMV-Tag2B-hPMC2. The insert was blunted and cloned into BglII digested and blunted pEGFP-C3 vector (Clonetech).
The expression vectors for the wild type human estrogen receptor α and β have been described previously (12, 13) .
To construct pBD-GAL4-ERβ(EF), which encodes the EF domain of ERβ cloned in frame with the DNA binding domain of GAL4, CMV-ERβ was digested with KpnI/SmaI, blunted, and inserted into SalI-digested, blunted pBD-GAL4-Cam (Stratagene, La Jolla, CA). To construct pGEX2T-ERβ, which encodes full-length and FLAGepitope tagged ERβ in frame with GST, FLAG-ERβ-BSII-SK+ was digested with
XbaI/HindIII. The insert was blunted and cloned into BamHI digested and blunted pGEX2T. The plasmid pCMVβ (Clonetech, Palo Alto, CA), which encodes the β-galactosidase gene, was used as an internal control for transfection efficiency in all experiments. from HIS3 + colonies using both filter lift or liquid assays (14) .
HIS3 + colonies exhibiting high β-galactosidase activity (LacZ + colonies) were further tested for interaction with the estrogen receptor. The yeast two hybrid screenings used to test interactions of putative EpRE-interacting clones with the estrogen receptor were described previously (14) . To establish interaction of promising clones with ERβ, a standard two-hybrid strategy was used wherein library plasmids encoding putative EpRE-interacting clones were also transformed into YRG2 yeast strain containing pBD-GAL-ERβ(EF) and plated into media lacking histidine. β-galactosidase activities were determined from HIS3 + colonies.
To recover library plasmids, total DNA from HIS3 +, LacZ + colonies was isolated and used to transform Escherichia coli (XLI-Blu MRF' strain from Stratagene). To ensure that the correct cDNAs were isolated, library plasmids were transformed back into the YM4271 yeast strain containing EpRE-pHISi-1 and EpRE-pLacZi, or EpREmut-pLacZi reporter vectors, plated onto media lacking histidine, and tested for β-galactosidase activity. The cDNAs were also transformed back into the YRG2 yeast strain containing pBD-GAL-ERβ(EF). 
GST-pull down assays. For the in vitro-interaction assays, five hundred micrograms of
Escherichia coli bacteria crude extracts containing GST-hPMC2 fusion protein were incubated at 4 C with 50 µl of glutathione Sepharose beads (50% slurry; Pharmacia; Piscataway, NJ) for 2.5
h. After two washes with 1 ml NENT (100 mM NaCl; 1 mM EDTA, 0.5% NP-40; 20 mM Tris, pH 7.9; 0.5% milk) and two washes with 1 ml binding buffer (20 mM HEPES, pH 7.9; 10% vol/vol glycerol; 60 mM NaCl; 1 mM dithiothreitol; 6 mM MgCl2; 1 mM EDTA) the beads were incubated with 5 µl of in vitro translated ERα or ERβ overnight at 4 C. The beads were then washed three times with 1 ml NET and two times with 1 ml binding buffer. After washing, bound protein was eluted with 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0 and boiled in SDS sample buffer. The protein samples were then analyzed by SDS-PAGE. The gel was dried and radiolabeled protein detected by autoradiography.
Cell Culture and Transfections. MDA-MB-231 and HepG2 cells were maintained and transfected as previously described (3, 16) . Cells were seeded for transfection in 100-mm dish in Improved Minimum Essential Media (IMEM) minus phenol red containing 5% CDCS. Cells at 30-50% of confluence were transfected by the CaPO4 coprecipitation method 48 h later with 2 µg of EpRE (wild type or mutated)-containing reporter constructs, ERβ expression vector, hPMC2 expression vector, and 1.5 µg pCMVβ β-galactosidase internal control plasmid. Carrier DNA pTZ19R was added to adjust total DNA to 15 ug. Cells remained in contact with the precipitate for 5 h and were then subjected to a 2.5-min glycerol shock (20% in IMEM minus phenol red plus 5% CDCS). Cells were rinsed with HBSS and given fresh media with or without hormones. All cells were harvested 24 h after hormone treatment. Extracts were prepared in 200 µl of 250 mM Tris HCl (pH 7.5) using three freeze-thaw cycles. β-galactosidase activity, which was measured to normalize for transfection efficiency, and CAT activity were assayed as previously described (17) .
Intracellular Localization of hPMC2. The pEGFP-hPMC2 vector was transfected into MDA- 
RESULTS
Identification of EpRE-binding and ER-interacting factors
hPMC2 interacts with the ER and binds to the EpRE in in vitro assays
The interaction of hPMC2 with the ERα and ERβ was examined in vitro in GST-pull down assays. in vitro translated and radiolabeled ERβ was retained in a column wherein hPMC2
was expressed a fusion protein with GST bound to a Glutathione-Sepharose indicating a direct interaction between hPMC2 and ERβ (Fig.2) . The interaction of hPMC2 with ERβ appears to be stronger when compared to its interaction to ERα. With regards to the effects of ligand on the interaction of ERβ with hPMC2, the strength of interaction of hPMC2 with ERβ can be described as follows: tamoxifen-liganded ERβ = unliganded ERβ > estrogen-liganded ERβ.
To verify binding of hPMC2 to the EpRE, the interaction of purified FLAG-hPMC2 protein ( Fig. 3A) with radiolabeled EpRE was examined in gel shift assays. A shifted DNAprotein complex is evident in samples containing purified hPMC2 but not with control extracts (Fig. 3B) . Binding of hPMC2 to the EpRE occurred in a dose-dependent manner. The DNAprotein complex was competed by excess amounts of unlabeled EpRE but not mutated EpRE or Novel Regulator of QR Transcriptional Activity wild type ERE (Fig. 3C) . A supershifted complex was observed in the presence of FLAG antibody. These studies indicate that hPMC2 interacted with the EpRE in a specific manner.
Because our GST pull down assays indicate the hPMC2 interacts with ERβ and more strongly so than with ERα, we examined the effect of purified ERβ (Fig.3A ) on the ability of hPMC2 to bind to the EpRE. When purified hPMC2 was coincubated with purified ERβ we observed a more intense DNA-protein complex band as well as supershifted bands when compared to hPMC2 alone (Fig. 3D) . Increased binding was observed in the absence of ligand and in the presence of the antiestrogen TOT. These results suggest an enhancement of the ability of hPMC2 to bind to the EpRE in the presence of ERβ. The DNA-protein complex observed in the presence of hPMC2 and ERβ was slightly supershifted and immunodepleted in the presence of ERβ antibody (Fig. 3D) suggesting that an interaction between ERβ and hPMC2 is involved in the enhancement of hPMC2 binding to the EpRE.
The ability of hPMC2 to bind to the EpRE as well as interact with the ER is supported by
experiments examining intracellular localization of hPMC2. Using fluorescence microscopy we observed that transiently transfected GFP-tagged hPMC2 can be localized primarily in the nucleus (Fig.4) . GFP vector alone showed cytoplasmic and nuclear localization, and GFPtagged prenylcysteine carboxyl methyltransferase (PMCT) that has been reported to exhibit primarily non-nuclear localization (24) did so under our experimental conditions. conditions wherein suboptimal concentrations of ERβ was cotransfected, hPMC2 was also able to activate EpRE activity in another cell line, HepG2 (Fig.6A) hPMC2 was then tested for its ability to regulate the activity of reporter construct containing QR gene 5' regulatory region and promoter region. No activation of this promoter was evident with hPMC2 alone, but when hPMC2 was cotransfected with suboptimal concentrations of ERβ, a more significant activation of the wild type EpRE-containing CAT reporter was observed (Fig. 6B) . No activation by hPMC2 was observed with the reporter construct wherein the EpRE containing region was deleted (NQO1 0.365 CAT). Thus hPMC2 was able to activate QR gene transcriptional activity in the presence of ERβ and this activation is mediated through the EpRE.
DISCUSSION
Novel Regulator of QR Transcriptional Activity
We report the identification of a novel EpRE binding factor using yeast genetic screenings. Binding of hPMC2 to the EpRE was verified using in vitro gel shift assays. The binding of hPMC2 to the EpRE induced an increase in EpRE enhancer activity. ERβ interacts with hPMC2 and enhanced hPMC2 induction of EpRE enhancer activity. Nuclear localization of hPMC2 supports the interaction of this protein with the ER as well as the ability to regulate transcription. We propose that the interaction of ERβ with factors that bind to the EpRE such as hPMC2 is involved in antiestrogen-liganded ERβ mediated induction of QR transcriptional activity.
XPMC2 was originally cloned as a gene involved in cell cycle regulation (19) .
Convergence of signaling pathways involved in the control of the response to oxidative stress and mitogenic signaling pathways is supported by previous reports on the ARE-dependent induction of phase II detoxifying enzymes by Mitogen-Activated Protein Kinase (MAPK) and ERK2 kinase (26) . XPMC2 prevents mitotic catastrophe in yeast resulting from disruption of Cdc2 kinase regulation of Wee1 and Mik1 kinase activities (19) . Control of Cdc2 kinase is a key step in controlling cell cycle transition from G1 to S phase and G2 to M (27) . Wee1 and Mik1 kinase negatively regulate Cdc2 kinases by phosphorylating a conserved tyrosine residue (28).
XPMC2 was found to be a substrate for Cdc2 kinase, and XPMC2 acts as a negative cell cycle regulator by competing with mitotic substrates for phosphorylation by Cdc2 kinase (19) . The target of XPMC2 action is unknown. hPMC2 may act as a negative cell cycle regulator by its regulation of QR transcriptional activity. The activation of anticancer quinones by QR results in enhanced cellular levels of reactive oxygen species (29) . Increased levels of reactive oxygen species affects the efferent pathways involved in cell cycle control, leading to p21 induction (29) . Our findings support a model for ER-mediated regulation of QR transcriptional activity which involves the interaction of the ER with activators of EpRE activity. Our previous findings indicate that ERβ is a stronger activator of QR transcriptional activity than ERα (12) . In the present studies we observed that hPMC2 interacts more strongly with ERβ when compared to We have previously reported that antiestrogen-liganded ER, and not unliganded ER or ER bound to estrogens, activates QR gene transcriptional activity (3, 12) . Moreover, in the present studies unliganded ERβ did not enhance hPMC2 induction of QR transcriptional activity. Fold Induction pNQO1hARE-TK-CAT   50 100  25 50  25 50  25 50  +  -----------TBHQ  -----+  +  ---+  -E2  -------+  +  --+  TOT hPMC2 ERβ hPMC2 (100) +ERβ 
